Vectors and strategies for nonviral cancer gene therapy

Expert Opinion on Biological Therapy

Volumn 16, Issue 4, 2016, Pages 443-461

  Pahle, Jessica ^a   Walther, Wolfgang ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Cancer; Gene therapy; Gene transfer; Nonviral vectors

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; APTAMER; MICRORNA; OLIGODEOXYNUCLEOTIDE; PLASMID VECTOR; SHORT HAIRPIN RNA; SMALL INTERFERING RNA;

CANCER GENE THERAPY; DNA IMMUNIZATION; ELECTROPORATION; GENE EXPRESSION; GENE REPRESSION; GENE SILENCING; HUMAN; NONHUMAN; NONVIRAL GENE THERAPY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; RNA IMMUNIZATION; RNA INTERFERENCE; SUICIDE GENE THERAPY; GENE THERAPY; GENE TRANSFER; GENE VECTOR; GENETICS; NEOPLASMS; PROCEDURES; TRENDS; TUMOR GENE;

GENE TRANSFER TECHNIQUES; GENES, NEOPLASM; GENETIC THERAPY; GENETIC VECTORS; HUMANS; MICRORNAS; NEOPLASMS;

EID: 84954306120     PISSN: 14712598     EISSN: 17447682     Source Type: Journal    
DOI: 10.1517/14712598.2016.1134480     Document Type: Review

References (120)

1. Ginn SL, Alexander IE, Edelstein ML. Gene therapy clinical trials worldwide to 2012-an update. J Gene Med. 2013;15(2):65-77. doi:10. 1002/jgm. 2698.
2. Gillet JP, Macadangdang B, Fathke RL, et al. The development of gene therapy: from monogenic recessive disorders to complex diseases such as cancer. Methods Mol Biol. 2009;542:5-54.
3. Walther W, Stein U. Viral vectors for gene transfer: a review of their use in the treatment of human diseases. Drugs. 2000;60:249-271. doi:10. 2165/00003495-200060020-00002.
4. Walther W, Schlag PM, Stein U. Local gene therapy of solid tumors. In: Kratz F, Senter P, Steinhagen H, editors. Drug delivery in oncology. Weinheim: Wiley-VCH; 2011. p. 1391-1414.
5. Lu C, Stewart DJ, Lee JJ, et al. Phase I clinical trial of systemically administered TUSC2(FUS1)-nanoparticles mediating functional gene transfer in humans. PLoS One. 2012;7:e34833. doi:10. 1371/journal. pone. 0034833
6. Senzer N, Nemunaitis J, Nemunaitis D, et al. Phase I study of a systemically delivered p53 nanoparticle in advanced solid tumors. Mol Ther. 2013;21:1096-1103. doi:10. 1038/ mt. 2013. 32.
7. Zarogoulidis P, Darwiche K, Sakkas A, et al. Suicide gene therapy for cancer-current strategies. J Genet Syndr Gene Ther. 2013 Aug 9;4. pii: 16849.
8. Walther W, Petkov S, Kuvardina ON, et al. Novel Clostridium perfringens enterotoxin suicide gene therapy for selective treatment of claudin-3-and 4-overexpressing tumors. Gene Ther. 2012;19:494-503. doi:10. 1038/ gt. 2011. 136.
9. Di Stasi A, Tey SK, Dotti G, et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med. 2011;365:1673-1683. doi:10. 1056/NEJMoa0910383.
10. Nakhlband A, Barar J, Bidmeshkipour A, et al. Bioimpacts of anti epidermal growth receptor antisense complexed with polyamidoamine dendrimers in human lung epithelial adenocarcinoma cells. J Biomed Nanotechnol. 2010;6:360-369. doi:10. 1166/jbn. 2010. 1131.
11. Zhao FJ, Zhang SL, Ma L, et al. Inhibitory effects of c-erbB-2 antisense oligonucleotide transfection on uterine endometrial cancer Ishikawa cell lines. Eur J Gynaecol Oncol. 2009;30:54-59.
12. Loriot Y, Mordant P, Brown BD, et al. Inhibition of BCL-2 in small cell lung cancer cell lines with oblimersen, an antisense BCL-2 oligodeoxynucleotide (ODN): in vitro and in vivo enhancement of radiation response. Anticancer Res. 2010;30:3869-3878.
13. Moulder SL, Symmans WF, Booser DJ, et al. Phase I/II study of G3139 (Bcl-2 antisense oligonucleotide) incombination with doxorubicin and docetaxel in breast cancer. Clin Cancer Res. 2008;14:7909-7916. doi:10. 1158/ 1078-0432. CCR-08-1104.
14. Fidias P, Pennell NA, Boral AL, et al. Phase I study of the c-raf-1 antisense oligonucleotide ISIS 5132 in combination with carboplatin and paclitaxel in patients with previously untreated, advanced non-small cell lung cancer. J Thorac Oncol. 2009;4:1156-1162. doi:10. 1097/ JTO. 0b013e3181b6be12.
15. Kesharwani P, Gajbhiye V, Jain NK. A review of nanocarriers for the delivery of small interfering RNA. Biomaterials. 2012;33:7138-7150. doi:10. 1016/j. biomaterials. 2012. 06. 068.
16. Carson AR, McTiernan CF, Lavery L, et al. Ultrasoundtargeted microbubble destruction to deliver siRNA cancer therapy. Cancer Res. 2012;72:6191-6199. doi:10. 1158/ 0008-5472. CAN-11-4079.
17. Santel A, Aleku M, Röder N, et al. Atu027 prevents pulmonary metastasis in experimental and spontaneous mouse metastasis models. Clin Cancer Res. 2010;16:5469-5480. doi:10. 1158/1078-0432. CCR-10-0613.
18. Strumberg D, Schultheis B, Traugott U, et al. Phase I clinical development of Atu027, a siRNA formulation targeting PKN3 in patients with advanced solid tumors. Int J Clin Pharmacol Ther. 2012;50:76-78. doi:10. 5414/ CPP50076.
19. Zhang X, Zhang J, Wang L, et al. Therapeutic effects of STAT3 decoy oligodeoxynucleotide on human lung cancer in xenograft mice. BMC Cancer. 2007;7:149.
20. Sen M, Thomas SM, Kim S, et al. First-in-human trial of a STAT3 decoy oligonucleotide in head and neck tumors: implications for cancer therapy. Cancer Discov. 2012;2:694-705. doi:10. 1158/2159-8290. CD-12-0191.
21. Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet. 2009;10:704-714. doi:10. 1038/nrg2634.
22. Jiao X, Zhao L, Ma M, et al. MiR-181a enhances drug sensitivity in mitoxantone-resistant breast cancer cells by targeting breast cancer resistance protein (BCRP/ ABCG2). Breast Cancer Res Treat. 2013;139:717-730. doi:10. 1007/s10549-013-2607-x.
23. Zhi F, Dong H, Jia X, et al. Functionalized graphene oxide mediated adriamycin delivery and miR-21 gene silencing to overcome tumor multidrug resistance in vitro. PLoS One. 2013;8:e60034. doi:10. 1371/journal. pone. 0060034.
24. Fioretti D, Iurescia S, Fazio VM, et al. DNA vaccines: developing new strategies against cancer. J Biomed Biotechnol. 2010;2010:174378. doi:10. 1155/2010/174378.
25. Senovilla L, Vacchelli E, Garcia P, et al. Trial watch: DNA vaccines for cancer therapy. Oncoimmunology. 2013;2: e23803. doi:10. 4161/onci. 23803.
26. Soong R-S, Trieu J, Lee SY, et al. Xenogeneic human p53 DNA vaccination by electroporation breaks immune tolerance to control murine tumors expressing mouse p53. PLoS One. 2013;8:e56912. doi:10. 1371/journal. pone. 0056912.
27. Pollard C, De Koker S, Saelens X, et al. Challenges and advances towards the rational design of mRNA vaccines. Trends Mol Med. 2013;19:705-713. doi:10. 1016/j. molmed. 2013. 09. 002.
28. Weide B, Carralot JP, Reese A, et al. Results of the first phase I/II clinical vaccination trial with direct injection of mRNA. J Immunother. 2008;31:180-188. doi:10. 1097/ CJI. 0b013e31815ce501.
29. Kreiter S, Selmi A, Diken M, et al. Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity. Cancer Res. 2010;70:9031-9040. doi:10. 1158/0008-5472. CAN-10-0699.
30. Rittig SM, Haentschel M, Weimer KJ, et al. Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients. Mol Ther. 2011;19:990-999. doi:10. 1038/mt. 2010. 289.
31. Kreiter S, Diken M, Selmi A, et al. Tumor vaccination using messenger RNA: prospects of a future therapy. Curr Opin Immunol. 2011;23:399-406. doi:10. 1016/j. coi. 2011. 03. 007.
32. Schleef M, Blaesen M. Production of plasmid DNA as a pharmaceutical. Methods Mol Biol. 2009;542:471-495.
33. Wu C, Lin J, Hong M, et al. Combinatorial control of suicide gene expression by tissue-specific promoter and microRNA regulation for cancer therapy. Mol Ther. 2009;17:2058-2066. doi:10. 1038/mt. 2009. 225.
34. Hackett PB, Largaespada DA, Cooper LJ. A transposon and transposase system for human application. Mol Ther. 2010;18:674-683. doi:10. 1038/mt. 2010. 2.
35. Muñoz-López M, García-Pérez JL. DNA transposons: nature and applications in genomics. Curr Genomics. 2010;11:115-128. doi:10. 2174/138920210790886871.
36. Vyazunova I, Maklakova VI, Berman S, et al. Sleeping Beauty mouse models identify candidate genes involved in gliomagenesis. PLoS One. 2014;9:e113489. doi:10. 1371/journal. pone. 0113489.
37. Takeda H, Wei Z, Koso H, et al. Transposon mutagenesis identifies genes and evolutionary forces driving gastrointestinal tract tumor progression. Nat Genet. 2015;47:142-150. doi:10. 1038/ng. 3175.
38. Moriarity BS, Otto GM, Rahrmann EP, et al. A Sleeping Beauty forward genetic screen identifies new genes andpathways driving osteosarcoma development and metastasis. Nat Genet. 2015;47:615-624. doi:10. 1038/ ng. 3293.
39. Ivics Z, Izsvák Z. Nonviral gene delivery with the sleeping beauty transposon system. Hum Gene Ther. 2011;22: 1043-1051. doi:10. 1089/hum. 2011. 143.
40. Hou X, Du Y, Deng Y, et al. Sleeping Beauty transposon system for genetic etiological research and gene therapy of cancers. Cancer Biol Ther. 2015;16:8-16. doi:10. 4161/ 15384047. 2014. 987548.
41. Singh H, Manuri PR, Olivares S, et al. Redirecting specificity of T-cell populations for CD19 using the Sleeping Beauty system. Cancer Res. 2008;68:2961-2971. doi:10. 1158/0008-5472. CAN-07-5600.
42. Kebriaei P, Huls H, Jena B, et al. Infusing CD19-directed T cells to augment disease control in patients undergoing autologous hematopoietic stem-cell transplantation for advanced B-lymphoid malignancies. Hum Gene Ther. 2012;23:444-450. doi:10. 1089/hum. 2011. 167.
43. Torikai H, Reik A, Liu P-Q, et al. A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR. Blood. 2012;119:5697-5705. doi:10. 1182/blood-2011-10-388512.
44. Huang G, Yu L, Cooper LJN, et al. Genetically modified T cells targeting interleukin-11 receptor-chain kill human osteosarcoma cells and induce the regression of established osteosarcoma lung metastases. Cancer Res. 2012;72:271-281. doi:10. 1158/0008-5472. CAN-11-2778.
45. Belur LR, Podetz-Pedersen KM, Sorenson BS, et al. Inhibition of angiogenesis and suppression of colorectal cancer metastatic to the liver using the Sleeping Beauty Transposon System. Mol Cancer. 2011;10:14. doi:10. 1186/ 1476-4598-10-93.
46. Clinical trials use Sleeping Beauty gene transfer to create CAR T cells. MD Anderson Cancer Center. Available from: http://www. mdanderson. org/newsroom/news-releases/ 2013/car-t-cells. html.
47. Huye LE, Nakazawa Y, Patel MP, et al. Combining mTor inhibitors with rapamycin-resistant T cells: a twopronged approach to tumor elimination. Mol Ther. 2013;19:2239-2248. doi:10. 1038/mt. 2011. 179.
48. Nakazawa Y, Huye LE, Salsman VS, et al. PiggyBacmediated cancer immunotherapy using EBV-specific cytotoxic T-cells expressing HER2-specific chimeric antigen receptor. Mol Ther. 2011;19:2133-2143. doi:10. 1038/ mt. 2011. 131.
49. Haase R, Magnusson T, Su B, et al. Generation of a tumorand tissue-specific episomal non-viral vector system. BMC Biotechnol. 2013;13:49.
50. Lipps HJ, Jenke ACW, Nehlsen K, et al. Chromosomebased vectors for gene therapy. Gene. 2003;304:23-33. doi:10. 1016/S0378-1119(02)01215-5.
51. Heinz N, Broll S, Schleef M, et al. Filling a gap : S/MARbased replicating minicircles. In: Cohen-Haguenauer O, editor. The Clinibook: Clinical Gene Transfer. EDP Sciences. 2012; p. 271-277.
52. Bode J, Kohwi Y, Dickinson L, et al. Biological significance of unwinding capability of nuclear matrix-associating DNAs. Science. 1992;255:195-197. doi:10. 1126/science. 1553545.
53. Linnemann AK, Krawetz SA. Silencing by nuclear matrix attachment distinguishes cell-type specificity: association with increased proliferation capacity. Nucleic Acids Res. 2009;37:2779-2788. doi:10. 1093/nar/gkp135.
54. Wong SP, Harbottle RP. Genetic modification of dividing cells using episomally maintained S/MAR DNA vectors. Mol Ther Nucleic Acids. 2013;2:e115. doi:10. 1038/ mtna. 2013. 40.
55. Argyros O, Wong SP, Harbottle RP. Non-viral episomal modification of cells using S/MAR elements. Expert Opin Biol Ther. 2015;11:1177-1191. doi:10. 1517/14712598. 2011. 582035.
56. Jenke ACW, Wilhelm AD, Orth V, et al. Long-term suppression of hepatitis B virus replication by short hairpin RNA expression using the scaffold/matrix attachment region-based replicating vector system pEPI-1. Antimicrob Agents Chemother. 2008;52:2355-2359. doi:10. 1128/AAC. 00067-08.
57. Tangudu NK, Verma VK, Clemons TD, et al. RNA interference using c-Myc-conjugated nanoparticles suppresses breast and colorectal cancer models. Mol Cancer Ther. 2015;14:1259-1269. doi:10. 1158/1535-7163. MCT-14-0970.
58. Marie C, Vandermeulen G, Quiviger M, et al. pFARs, plasmids free of antibiotic resistance markers, display highlevel transgene expression in muscle, skin and tumour cells. J Gene Med. 2010;12:323-332. doi:10. 1002/jgm. 1495.
59. Al-Dosari MS, Gao X. Nonviral gene delivery: principle, limitations, and recent progress. AAPS J. 2009;11:671-681 doi:10. 1208/s12248-009-9143-y.
60. Gill DR, Pringle IA, Hyde SC. Progress and prospects: the design and production of plasmid vectors. Gene Ther. 2009;16:165-171. doi:10. 1038/gt. 2008. 183.
61. Mayrhofer P, Blaesen M, Schleef M, et al. Minicircle-DNA production by site specific recombination and protein-DNA interaction chromatography. J Gene Med. 2008;10:1253-1269. doi:10. 1002/jgm. v10:11.
62. Ribeiro S, Mairhofer J, Madeira C, et al. Plasmid DNA size does affect nonviral gene delivery efficiency in stem cells. Cell Reprogram. 2012;14:130-137.
63. Zuo Y, Wu J, Xu Z, et al. Minicircle-oriP-IFN: a novel targeted gene therapeutic system for EBV positive human nasopharyngeal carcinoma. PLoS One. 2011;6: e19407. doi:10. 1371/journal. pone. 0019407.
64. Lu J, Zhang F, Kay MA. A mini-intronic plasmid (MIP): a novel robust transgene expression vector in vivo and in vitro. Mol Ther. 2013;21:954-963. doi:10. 1038/mt. 2013. 33.
65. Yu H, Jiang X, Tan KT, et al. Efficient production of superior dumbbell-shaped DNA minimal vectors for small hairpin RNA expression. Nucleic Acids Res. 2015;43:e120. doi:10. 1093/nar/gkv583.
66. Lara AR, Ramírez OT, Wunderlich M. Plasmid DNA production for therapeutic applications. Methods Mol Biol. 2012;824:271-303. doi:10. 1007/978-1-61779-433-9-2.
67. Kobelt D, Aumann J, Schmidt M, et al. Preclinical study on combined chemo-and nonviral gene therapy for sensitization of melanoma using a human TNF-alpha expressing MIDGE DNA vector. Mol Oncol. 2014;8:609-619 doi:10. 1016/j. molonc. 2013. 12. 019.
68. Köchling J, Prada J, Bahrami M, et al. Anti-tumor effect of DNA-based vaccination and dSLIM immunomodulatory molecules in mice with Ph+ acute lymphoblastic leukaemia. Vaccine. 2008;26:4669-4675. doi:10. 1016/j. vaccine. 2008. 06. 094.
69. Farooqi AA, Marwat Z, Muntane J. Antisense therapeutics in oncology: current status. Onco Targets Ther. 2014; 7:2035.
70. Baumann V, Winkler J. miRNA-based therapies: strategies and delivery platforms for oligonucleotide and non-oligonucleotide agents. Future Med Chem. 2014;6:1967-1984. doi:10. 4155/fmc. 14. 116.
71. Najar AG, Pashaei-Asl R, Omidi Y, et al. EGFR antisense oligonucleotides encapsulated with nanoparticles decrease EGFR, MAPK1 and STAT5 expression in a human colon cancer cell line. Asian Pac J Cancer Prev. 2013;14:495-498. doi:10. 7314/APJCP. 2013. 14. 1. 495.
72. Hau P, Jachimczak P, Bogdahn U. Treatment of malignant gliomas with TGF-2 antisense oligonucleotides. Expert Rev Anticancer Ther. 2009;9(11):1663-1674. doi:10. 1586/ era. 09. 138
73. Gutschner T, Hammerle M, Eissmann M, et al. The noncoding RNA MALAT1 is a critical regulator of the metastasis phenotype of lung cancer cells. Cancer Res. 2013;73:1180-1189. doi:10. 1158/0008-5472. CAN-12-2850.
74. Que-Gewirth NS, Sullenger BA. Gene therapy progress and prospects: RNA aptamers. Gene Ther. 2007;14:283-291 doi:10. 1038/sj. gt. 3302900.
75. Soundararajan S, Wang L, Sridharan V, et al. Plasma membrane nucleolin is a receptor for the anticancer aptamer AS1411 in MV4-11 leukemia cells. Mol Pharmacol. 2009;76:984-991. doi:10. 1124/mol. 109. 059683.
76. Li L, Hou J, Liu X, et al. Nucleolin-targeting liposomes guided by aptamer AS1411 for the delivery of siRNA for the treatment of malignant melanomas. Biomaterials. 2014;35:3840-3850. doi:10. 1016/j. biomaterials. 2014. 01. 026.
77. Rosenberg JE, Bambury RM, Van Allen EM, et al. A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma. Invest New Drugs. 2014;32:178-187. doi:10. 1007/s10637-013-0045-6.
78. Ma Y, Zhang X, Xu X, et al. STAT3 decoy oligodeoxynucleotides-loaded solid lipid nanoparticles induce cell death and inhibit invasion in ovarian cancer cells. PLoS One. 2015;10: e0124924. doi:10. 1371/journal. pone. 0124924.
79. Souissi I, Najjar I, Ah-Koon L, et al. A STAT3-decoy oligonucleotide induces cell death in a human colorectal carcinoma cell line by blocking nuclear transfer of STAT3 and STAT3-bound NF-B. BMC Cell Biol. 2011;12:14. doi:10. 1186/1471-2121-12-14.
80. Zhu X, Li Q, Li S, et al. HIF-1 decoy oligodeoxynucleotides inhibit HIF-1 signaling and breast cancer proliferation. Int J Oncol. 2015;46:215-222.
81. Shi KH, Jiang HL. Effects of nuclear factor of kappa B decoy oligodeoxynucleotides on murine with multiple myeloma. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2015;23:132-136.
82. Yoshioka K, Kuwahara H, Nishina K, et al. Recent progress and prospect in oligonucleotide therapeutics. Nihon Rinsho. 2015;73:1057-1065.
83. Tabernero J, Shapiro GI, LoRusso PM, et al. First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov. 2013;3:406-417. doi:10. 1158/2159-8290. CD-12-0429.
84. Chen W-X, Hu Q, Qiu M-T, et al. miR-221/222: promising biomarkers for breast cancer. Tumour Biol. 2013;34:1361-1370. doi:10. 1007/s13277-013-0750-y.
85. Kazuki Y. Oshimura M: human artificial chromosomes for gene delivery and the development of animal models. Mol Ther. 2011;19:1591-1601. doi:10. 1038/mt. 2011. 136.
86. Liu K-C, Lin B-S, Gao A-D, et al. Integrase-deficient lentivirus: opportunities and challenges for human gene therapy. Curr Gene Ther. 2014;14:352-364. doi:10. 2174/ 1566523214666140825124311.
87. Philippe S, Sarkis C, Barkats M, et al. Lentiviral vectors with a defective integrase allow efficient and sustained transgene expression in vitro and in vivo. Proc Natl Acad Sci U S A. 2006;103:17684-17689. doi:10. 1073/pnas. 0606197103.
88. Wang W, Li W, Ma N, et al. Non-viral gene delivery methods. Curr Pharm Biotechnol. 2013;14:46-60.
89. Manjila SB, Baby JN, Bijin EN, et al. Novel gene delivery systems. Int J Pharm Investig. 2013;3:1-7. doi:10. 4103/ 2230-973X. 108958.
90. Jin L, Zeng X, Liu M, et al. Current progress in gene delivery technology based on chemical methods and nano-carriers. Theranostics. 2014;4:240-255. doi:10. 7150/ thno. 6914.
91. Somani S, Dufès C. Transferrin-bearing dendrimers for cancer therapy: an update. Nanomedicine. 2015;10 (14):2125-2127. doi:10. 2217/nnm. 15. 93.
92. Duan X, Wang P, Men K, et al. Treating colon cancer with a suicide gene delivered by self-assembled cationic MPEG-PCL micelles. Nanoscale. 2012;4:2400-2407. doi:10. 1039/c2nr30079f.
93. Zhao Y, Huang L. Lipid nanoparticles for gene delivery. Adv Genet. 2014;88:13-36.
94. Oh MH, Kim JS, Lee JY, et al. Radio-opaque theranostic nanoemulsions with synergistic anti-cancer activity of paclitaxel and Bcl-2 siRNA. RSC Adv. 2013;3:14642. doi:10. 1039/c3ra40883c.
95. Tang Q, Cao B, Wu H, et al. Selective gene delivery to cancer cells using an integrated cationic amphiphilic peptide. Langmuir. 2012;28:16126-16132. doi:10. 1021/la303299s.
96. Goodwin T, Huang L. Nonviral vectors: we have come a long way, Chapter 1. In: Leaf Huang DL, Wagner E, editors. Nonviral vectors for gene therapy Lipid-and polymer-based gene transfer. Vol. 88. Academic Press; 2014. p. 1-12. doi:10. 1016/B978-0-12-800148-6. 00001-8.
97. Gaspar VM, Gonçalves C, de Melo-Diogo D, et al. Poly(2-ethyl-2-oxazoline)-PLA-g-PEI amphiphilic triblock micelles for co-delivery of minicircle DNA and chemotherapeutics. J Control Release. 2014;189:90-104. doi:10. 1016/j. jconrel. 2014. 06. 040.
98. Liu C, Liu F, Feng L, et al. The targeted co-delivery of DNA and doxorubicin to tumor cells via multifunctional PEIPEG based nanoparticles. Biomaterials. 2013;34:2547-2564. doi:10. 1016/j. biomaterials. 2012. 12. 038.
99. Eltoukhy AA, Siegwart DJ, Alabi CA, et al. Effect of molecular weight of amine end-modified poly(-amino ester)s on gene delivery efficiency and toxicity. Biomaterials. 2012;33:3594-3603. doi:10. 1016/j. biomaterials. 2012. 01. 046.
100. Majewski AP, Stahlschmidt U, Jérôme V, et al. PDMAEMAgrafted core-shell-corona particles for nonviral gene delivery and magnetic cell separation. Biomacromolecules. 2013;14:3081-3090. doi:10. 1021/bm400426f.
101. Liu X, Liu C, Laurini E, et al. Efficient delivery of sticky siRNA and potent gene silencing in a prostate cancer model using a generation 5 triethanolamine-core PAMAM dendrimer. Mol Pharm. 2012;9:470-481. doi:10. 1021/mp2006104.
102. Chuang C-C, Chang C-W. Complexation of bioreducible cationic polymers with gold nanoparticles for improving stability in serum and application on nonviral gene delivery. ACS Appl Mater Interfaces. 2015;7:7724-7731. doi:10. 1021/acsami. 5b00732.
103. Adeli M, Soleyman R, Beiranvand Z, et al. Carbon nanotubes in cancer therapy: a more precise look at the role of carbon nanotube-polymer interactions. Chem Soc Rev. 2013;42:5231. doi:10. 1039/c3cs35431h.
104. Li C, Li L, Keates AC. Targeting cancer gene therapy with magnetic nanoparticles. Oncotarget. 2012;3:365-370. doi:10. 18632/oncotarget.
105. Zilony N, Tzur-Balter A, Segal E, et al. Bombarding cancer: biolistic delivery of therapeutics using porous Si carriers. Sci Rep. 2013;3:2499. doi:10. 1038/srep02499.
106. Galling N, Kobelt D, Aumann J, et al. Intratumoral dispersion, retention, systemic biodistribution, and clearance of a small-size tumor necrosis factor-expressing MIDGE vector after nonviral in vivo jet-injection gene transfer. Hum Gene Ther Methods. 2012;23:264-270. doi:10. 1089/ hgtb. 2012. 049.
107. Hama S, Arata M, Nakamura I, et al. Prevention of tumor growth by needle-free jet injection of anti-C7orf24 siRNA. Cancer Gene Ther. 2012;19:553-557. doi:10. 1038/ cgt. 2012. 31.
108. Murakami T, Sunada Y. Plasmid DNA gene therapy by electroporation: principles and recent advances. Curr Gene Ther. 2011;11:447-456. doi:10. 2174/1566523 11798192860.
109. Calvet CY, André FM, Mir LM. Dual therapeutic benefit of electroporation-mediated DNA vaccination in vivo: enhanced gene transfer and adjuvant activity. Oncoimmunology. 2014;3:e28540. doi:10. 4161/onci. 28540.
110. Bosnjak M, Dolinsek T, Cemazar M, et al. Gene electrotransfer of plasmid AMEP, an integrin-targeted therapy, has antitumor and antiangiogenic action in murine B16 melanoma. Gene Ther. 2015;22:578-590. doi:10. 1038/ gt. 2015. 26.
111. Liao Z-K, Tsai K-C, Wang H-T, et al. Sonoporationmediated anti-angiogenic gene transfer into muscle effectively regresses distant orthotopic tumors. Cancer Gene Ther. 2011;19:171-180. doi:10. 1038/cgt. 2011. 73.
112. Pichon C, Kaddur K, Midoux P, et al. Recent advances in gene delivery with ultrasound and microbubbles. J Exp Nanosci. 2008;3:17-40. doi:10. 1186/1471-2407-7-149.
113. Zeghimi A, Escoffre J-M, Bouakaz A: Ultrastructural sonoporation bio-effects: comparative study on two human cancer cell lines. In: 2013 IEEE International Ultrasonics Symposium (IUS). IEEE; 2013. p. 61-64. doi:10. 1109/ ULTSYM. 2013. 0016.
114. Govindarajan S, Kitaura K, Takafuji M, et al. Gene delivery into human cancer cells by cationic lipid-mediated magnetofection. Int J Pharm. 2013;446:87-99. doi:10. 1016/j. ijpharm. 2013. 01. 055.
115. Prosen L, Prijic S, Music B, et al. Magnetofection: a reproducible method for gene delivery to melanoma cells. Biomed Res Int. 2013;2013:1-11. doi:10. 1155/2013/ 209452.
116. Singh A, Sahoo SK. Magnetic nanoparticles: a novel platform for cancer theranostics. Drug Discov Today. 2014;19:474-481. doi:10. 1016/j. drudis. 2013. 10. 005.
117. Thomas R, Park I-K, Jeong YY. Magnetic iron oxide nanoparticles for multimodal imaging and therapy of cancer. Int J Mol Sci. 2013;14:15910-15930. doi:10. 3390/ijms140815910.
118. Gaj T, Gersbach CA, Barbas CF. ZFN, TALEN, and CRISPR/ Cas-based methods for genome engineering. Trends Biotechnol. 2013;31:397-405. doi:10. 1016/j. tibtech. 2013. 04. 004.
119. Zhang M, Wang F, Li S, et al. TALE: a tale of genome editing. Prog Biophys Mol Biol. 2014;114:25-32. doi:10. 1016/j. pbiomolbio. 2013. 11. 006.
120. Mali P, Esvelt KM, Church GM. Cas9 as a versatile tool for engineering biology. Nat Methods. 2013;10:957-963. doi:10. 1038/nmeth. 2649.